Targeted delivery of nerve growth factor to the cholinergic basal forebrain of Alzheimer’s disease patients: application of a second-generation encapsulated cell biodelivery device

Table 1 Adverse events during the 6-month trial period

Adverse event	Number
Delirium	2
Headache	7
Hypertension	1
Subdural haematoma	1
Fatigue	1
Nasopharyngitis (common cold)	1
Abnormal clinical chemistry findings^a	1
Nausea/vomiting	1
Herpes simplex blister	1
Total number	16

ISSN: 1758-9193